BR9601276A - Solução de interferona aquosa - Google Patents

Solução de interferona aquosa

Info

Publication number
BR9601276A
BR9601276A BR9601276A BR9601276A BR9601276A BR 9601276 A BR9601276 A BR 9601276A BR 9601276 A BR9601276 A BR 9601276A BR 9601276 A BR9601276 A BR 9601276A BR 9601276 A BR9601276 A BR 9601276A
Authority
BR
Brazil
Prior art keywords
interferon solution
aqueous interferon
aqueous
solution
interferon
Prior art date
Application number
BR9601276A
Other languages
English (en)
Inventor
Guenter Gross
Sabino Del Terzo
Saran Kandakuri Kumar
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR9601276A publication Critical patent/BR9601276A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Detergent Compositions (AREA)
BR9601276A 1995-04-06 1996-04-04 Solução de interferona aquosa BR9601276A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95105166 1995-04-06

Publications (1)

Publication Number Publication Date
BR9601276A true BR9601276A (pt) 1998-01-13

Family

ID=8219166

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9601276A BR9601276A (pt) 1995-04-06 1996-04-04 Solução de interferona aquosa

Country Status (31)

Country Link
US (1) US5762923A (pt)
EP (1) EP0736303B1 (pt)
JP (1) JP2758154B2 (pt)
KR (1) KR100212346B1 (pt)
CN (1) CN1066065C (pt)
AR (1) AR002932A1 (pt)
AT (1) ATE183650T1 (pt)
AU (1) AU685356B2 (pt)
BR (1) BR9601276A (pt)
CA (1) CA2172664C (pt)
CO (1) CO4750807A1 (pt)
CY (1) CY2194B1 (pt)
CZ (1) CZ287626B6 (pt)
DE (1) DE69603894T2 (pt)
DK (1) DK0736303T3 (pt)
ES (1) ES2136910T3 (pt)
GR (1) GR3031775T3 (pt)
HU (1) HU227643B1 (pt)
IL (1) IL117752A (pt)
MA (1) MA23838A1 (pt)
MY (1) MY113594A (pt)
NO (1) NO316801B1 (pt)
NZ (1) NZ286300A (pt)
PE (1) PE38897A1 (pt)
PL (1) PL183873B1 (pt)
RU (1) RU2113845C1 (pt)
SA (1) SA96160728B1 (pt)
SG (1) SG52806A1 (pt)
TR (1) TR199600287A2 (pt)
TW (1) TW426523B (pt)
ZA (1) ZA962553B (pt)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6402718B1 (en) 1992-08-17 2002-06-11 Medrad, Inc. Front-loading medical injector and syringe for use therewith
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
JP4878664B2 (ja) * 1996-12-24 2012-02-15 バイオジェン・アイデック・エムエイ・インコーポレイテッド 安定な液体インターフェロン処方物
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
WO1999048535A1 (en) * 1998-03-26 1999-09-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
ATE367828T1 (de) * 1998-04-03 2007-08-15 Novartis Vaccines & Diagnostic Igf-enthaltende injizierbare formulierungen enthaltend succinate als puffermittel
CA2331823A1 (en) 1998-05-15 1999-11-25 Schering Corporation Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection
CZ298681B6 (cs) * 1998-06-08 2007-12-19 F. Hoffmann-La Roche Ag Lécivo pro lécení infekcí chronické hepatitis C
CN1309567A (zh) † 1998-07-23 2001-08-22 伊莱利利公司 Fsh和fsh变体制剂,产品和方法
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
ES2245114T3 (es) 1998-08-06 2005-12-16 Mountain View Pharmaceuticals, Inc. Conjugados de peg-oxidasa de urato y su uso.
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
WO2000037096A2 (en) * 1998-12-22 2000-06-29 Schering Corporation Treatment of hepatitis c virus infections with interleukin-10
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US6923966B2 (en) * 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
DK1535622T3 (da) 1999-04-08 2009-04-20 Schering Corp Melanomterapi
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
KR100399156B1 (ko) * 1999-11-19 2003-09-26 주식회사 엘지생명과학 α-인터페론의 용액제형
CN1175901C (zh) * 1999-12-06 2004-11-17 天津华立达生物工程有限公司 一种稳定的干扰素水溶液
EP2206720A1 (en) 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Albumin fusion proteins
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
AU3070702A (en) 2000-11-07 2002-05-21 Chiron Corp Stabilized inteferon compositions
CN1245215C (zh) 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US8551469B2 (en) 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
JP2002265383A (ja) * 2001-03-14 2002-09-18 Mitsubishi Pharma Corp インターフェロンα注射用液状製剤
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
WO2002083165A1 (fr) * 2001-04-10 2002-10-24 Sumitomo Pharmaceuticals Co., Ltd. Preparations stables destinees a etre injectees
LT4947B (lt) 2001-09-26 2002-08-26 Biotechnologijos Institutas Interferono alfa farmacinė kompozicija
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
WO2003097083A1 (en) 2002-05-21 2003-11-27 Daiichi Suntory Pharma Co.,Ltd. Medicinal compositions containing ghrelin
RU2238758C2 (ru) * 2002-07-24 2004-10-27 Закрытое акционерное общество "Вектор-Медика" Водный раствор интерферона-альфа-два человека для инъекций
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
CA2518903C (en) 2003-04-02 2013-02-05 Ares Trading S.A. Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
AR044302A1 (es) * 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
WO2004112826A1 (en) 2003-06-20 2004-12-29 Ares Trading Sa Freeze-dried fsh / lh formulations
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
AR045258A1 (es) * 2003-08-21 2005-10-19 Altana Pharma Ag Un producto farmaceutico para inyeccion
US7585647B2 (en) 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
EP2327724A3 (en) 2004-02-02 2011-07-27 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
JP2007538048A (ja) 2004-05-17 2007-12-27 アレス トレーディング ソシエテ アノニム ヒドロゲル・インターフェロン製剤
UA92146C2 (ru) * 2004-06-01 2010-10-11 Эйрэс Трейдинг С.А. Стабилизированная жидкая композиция, которая содержит интерферон
EP1750750B1 (en) 2004-06-01 2012-02-01 Ares Trading S.A. Method of stabilizing proteins
RU2255729C1 (ru) * 2004-07-26 2005-07-10 Общество С Ограниченной Ответственностью "Фармапарк" Препарат интерферона альфа в форме стабильного водного раствора для инъекций
DE602005022895D1 (de) 2004-08-12 2010-09-23 Schering Corp Stabile pegylierte interferon-formulierung
CN101022822B (zh) * 2004-08-24 2012-06-27 第一三共株式会社 生理学活性肽的液体制剂
RU2270692C1 (ru) * 2004-11-04 2006-02-27 Валентина Васильевна Малиновская Пролонгированный раствор интерферона
HUE052976T2 (hu) 2005-04-11 2021-06-28 Horizon Pharma Rheumatology Llc Urát-oxidáz variáns formái és azok alkalmazása
ES2302402B1 (es) 2005-06-16 2009-05-08 Proyecto De Biomedicina Cima, S.L. Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
AU2006295340B2 (en) * 2005-08-05 2010-11-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
CU23432B6 (es) 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
WO2008026044A2 (en) * 2006-08-31 2008-03-06 Wockhardt Research Centre Pharmaceutical compositions of bupropion
CN104524567A (zh) 2007-01-16 2015-04-22 阿布维公司 用于治疗银屑病的方法
WO2008145323A1 (en) * 2007-05-31 2008-12-04 F. Hoffmann-La Roche Ag Pharmaceutical formulation for interferons
CA2698173C (en) * 2007-09-04 2015-02-03 Biosteed Gene Expression Tech. Co., Ltd. Interferon alpha 2b modified by polyethylene glycol, the preparation and use thereof
ES2386575T3 (es) * 2007-09-04 2012-08-23 Biosteed Gene Expression Tech. Co., Ltd. Interferón alfa 2a modificado por polietilenglicol, su proceso de síntesis y su aplicación
RU2010120674A (ru) * 2007-10-22 2011-11-27 Шеринг Корпорейшн (US) Полностью человеческие анти-vegf-антитела и способы их применения
BRPI0821029A2 (pt) 2007-12-20 2015-06-16 Merck Serono Sa Fomulações de peg-interferon-beta
EP2305309A2 (en) 2008-06-13 2011-04-06 Proyecto de Biomedicina Cima, S.L. Conjugates for the administration of biologically active compounds
WO2010033226A1 (en) * 2008-09-17 2010-03-25 Nektar Therapeutics Oligomer-protease inhibitor conjugates
HUP1200205A3 (en) 2009-06-25 2012-09-28 Savient Pharmaceuticals Method and kits for perdicting infusion reaction risk and antibody-mediated low of response by monitoring serum uric acid during pegylated uricare therapy
CN102101886A (zh) 2009-12-18 2011-06-22 四川辉阳生命工程股份有限公司 构象改变的重组干扰素晶体、其三维结构及应用
RU2447083C1 (ru) * 2010-07-20 2012-04-10 Закрытое Акционерное Общество "Биокад" НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ ВЫСОКООЧИЩЕННЫЙ СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА α С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ
KR101303388B1 (ko) * 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
CN102526758B (zh) * 2012-02-23 2013-02-13 北京三元基因工程有限公司 一种聚乙二醇化干扰素稳定的水溶液
TWI718086B (zh) 2013-01-07 2021-02-11 英屬維爾京群島商遠東超級實驗室有限公司 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
EP3200767A1 (en) * 2014-09-23 2017-08-09 F.Hoffmann-La Roche Ag Stable, benzyl alcohol-free aqueous solution formulations containing alpha-type interferon
CN110234340A (zh) 2016-11-11 2019-09-13 好利恩风湿病制药有限责任公司 泼尼松和尿酸酶分子的组合疗法及其用途
US20200237881A1 (en) 2019-01-30 2020-07-30 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
US12121566B2 (en) 2019-01-30 2024-10-22 Horizon Therapeutics Usa, Inc. Methods for treating gout
RU2768656C1 (ru) * 2021-09-10 2022-03-24 Илья Александрович Марков Противовирусное средство в жидкой форме и способ его приготовления
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61277633A (ja) * 1985-05-31 1986-12-08 Toray Ind Inc インタ−フエロン組成物
RU2007184C1 (ru) * 1985-11-25 1994-02-15 Научно-исследовательский институт эпидемиологии и микробиологии им.Н.Ф.Гамалеи РАМН Способ лечения сальмонеллезной инфекции
EP0284249A1 (en) * 1987-03-13 1988-09-28 Interferon Sciences, Inc. Lyophilized lymphokine composition
IL88233A (en) * 1987-11-03 1993-08-18 Genentech Inc Gamma interferon formulation
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
KR900701310A (ko) * 1988-11-14 1990-12-01 오스카 아끼히꼬 인터페론 경비투여용 제제
JPH0651642B2 (ja) * 1988-11-14 1994-07-06 大塚製薬株式会社 インターフェロン経鼻投与用製剤
CA2033714A1 (en) * 1990-01-25 1991-07-26 Alberto Ferro Pharmaceutical preparations
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
IL109350A (en) * 1993-05-12 2001-01-28 Genentech Inc Stable liquid compositions of gamma interferon

Also Published As

Publication number Publication date
IL117752A0 (en) 1996-08-04
AU5044696A (en) 1996-10-17
CZ287626B6 (en) 2001-01-17
KR960037063A (ko) 1996-11-19
SA96160728B1 (ar) 2005-05-04
TR199600287A2 (tr) 1997-03-21
NO961322L (no) 1996-10-07
DE69603894T2 (de) 2000-04-20
MA23838A1 (fr) 1996-12-31
KR100212346B1 (ko) 1999-08-02
CN1141808A (zh) 1997-02-05
MY113594A (en) 2002-04-30
HU9600857D0 (en) 1996-05-28
DK0736303T3 (da) 2000-01-10
EP0736303B1 (en) 1999-08-25
JPH08283176A (ja) 1996-10-29
CO4750807A1 (es) 1999-03-31
AR002932A1 (es) 1998-05-27
EP0736303A2 (en) 1996-10-09
RU2113845C1 (ru) 1998-06-27
SG52806A1 (en) 1998-09-28
HK1012232A1 (en) 1999-07-30
CA2172664C (en) 2000-10-03
ES2136910T3 (es) 1999-12-01
PL183873B1 (pl) 2002-07-31
PL313655A1 (en) 1996-10-14
US5762923A (en) 1998-06-09
IL117752A (en) 2000-11-21
NZ286300A (en) 1997-05-26
ZA962553B (en) 1996-10-07
CN1066065C (zh) 2001-05-23
NO961322D0 (no) 1996-04-01
DE69603894D1 (de) 1999-09-30
GR3031775T3 (en) 2000-02-29
CZ99496A3 (en) 1996-10-16
PE38897A1 (es) 1997-10-04
HUP9600857A3 (en) 1998-01-28
CY2194B1 (en) 2002-11-08
EP0736303A3 (en) 1997-02-26
TW426523B (en) 2001-03-21
CA2172664A1 (en) 1996-10-07
NO316801B1 (no) 2004-05-18
JP2758154B2 (ja) 1998-05-28
HU227643B1 (en) 2011-10-28
AU685356B2 (en) 1998-01-15
ATE183650T1 (de) 1999-09-15
HUP9600857A2 (en) 1997-08-28

Similar Documents

Publication Publication Date Title
BR9601276A (pt) Solução de interferona aquosa
DE59606873D1 (de) Spezialanzug
PT833828E (pt) Derivados de rapamicina
BR9609682A (pt) Foto-desinfetantes de baixa nuança
DK0822982T3 (da) Cyclomaltodextringlucanotransferasevarianter
BR9605434A (pt) Derivados de purin-6-ona
DE59605335D1 (de) Muldenkörper
BR9610239A (pt) Proteínas de fusão-alérgeno-xcd32
PT856007E (pt) Derivados de ciclopeptidos
BR9610597A (pt) Derivados de diarilalcenilamina
BR9607535A (pt) Arabinofuranodidase de aspergillus
BR9603508A (pt) Derivados de alquenil-benzoilguanidina
PT839024E (pt) Formulacoes de monensina
DK0827503T3 (da) Pyrrolidinylmethylindol-salt
DE59708205D1 (de) Wässrige bleichmittel
DE69513898D1 (de) Distanzstück
KR970005590U (ko) 차체의 크로스멤버
KR970005583U (ko) 자동차의 하부 차체
KR960028332U (ko) 시신관
KR970033137U (ko) 자동점멸장치
ID16384A (id) Larutan interferon
FI954223A0 (fi) Kappale
KR970009598U (ko) 캔 스트롱
BR7500505U (pt) Amolador de facas
SE9503429D0 (sv) Växelnav

Legal Events

Date Code Title Description
FB34 Technical and formal requirements: requirement - article 34 of industrial property law
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 20A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.